Compare
iTonic Holdings Ltd vs Guided Therapeutics Inc vs Hongchang International Co., Ltd vs Neuraxis, Inc
| Latest fiscal year | iTonic Holdings Ltd ITOC | Guided Therapeutics Inc GTHP | Hongchang International Co., Ltd HCILLast annual report: year ended 2024-12-31 | Neuraxis, Inc NRXS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 |
| Revenue | $523.0K | $767.0K | $2.87M | $3.57M |
| Revenue growth (YoY) | +16.7% | n/m | +7.1% | +32.9% |
| Gross margin | 62.6% | 74.4% | 6.3% | 84.2% |
| Operating margin | -991.7% | -309.3% | -13.4% | -219.4% |
| Net margin | -974.7% | -416.7% | -16.5% | -218.5% |
| Net income | -$5.10M | -$3.20M | -$472.4K | -$7.80M |
| EPS (Diluted) | -$0.32 | -$0.04 | $0.00 | -$0.95 |
| Operating cash flow | -$3.23M | -$1.07M | -$7.34M | -$6.43M |
| Free cash flow | -$3.24M | -$1.07M | -$11.36M | -$6.46M |
| Cash & equivalents | $1.49M | n/a | n/a | $4.97M |
| Total assets | $9.10M | $1.32M | $57.45M | $6.40M |
| Total liabilities | $969.8K | $7.33M | $18.68M | $3.00M |
| Shareholders' equity | $6.12M | -$6.01M | $38.77M | $3.40M |
| Return on year-end equity | -83.3% | n/a | -1.2% | -229.5% |
| Shares outstanding | n/a | 86.15M | 518.83M | 10.65M |
Revenue, most recent five fiscal years
| Fiscal year | iTonic Holdings Ltd | Guided Therapeutics Inc | Hongchang International Co., Ltd | Neuraxis, Inc |
|---|---|---|---|---|
| Latest | $523.0K Ended 2025-12-31 | $767.0K Ended 2025-12-31 | $2.87M Ended 2024-12-31 | $3.57M Ended 2025-12-31 |
| 1 year earlier | $448.2K Ended 2024-12-31 | $7.0K Ended 2024-12-31 | $2.68M Ended 2023-12-31 | $2.69M Ended 2024-12-31 |
| 2 years earlier | $628.6K Ended 2023-12-31 | $98.0K Ended 2023-12-31 | $79.0K Ended 2022-12-31 | $2.46M Ended 2023-12-31 |
| 3 years earlier | $679.8K Ended 2022-12-31 | $13.0K Ended 2022-12-31 | $96.5K Ended 2021-12-31 | $2.68M Ended 2022-12-31 |
| 4 years earlier | n/a | $81.0K Ended 2021-12-31 | $222.7K Ended 2020-12-31 | n/a |